A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3 Recruiting 700 enrolled Incyte Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Timeline

Start: 2026-03-05
Primary completion: 2028-12-29
Completion: 2029-09-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCA33890	Unknown	—	—
Background	Bevacizumab	Monoclonal antibody	—	—

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Summary

Timeline

Drugs

Indications